ecromeximab (KM-871) / Life Science Pharma, Kyowa Kirin - LARVOL DELTA

Computational exploration and anti-mycobacterial activity of potential inhibitors of Mycobacterium tuberculosis acetyl coenzyme A carboxylase as anti-tubercular agents. (PubMed, SAR QSAR Environ Res) - "In this study, we have performed molecular docking of the Maybridge database consisting of ~55,000 compounds in the active site of the protein with haloxyfop as a reference molecule, followed by molecular dynamics study and biological activity determination of prioritized compounds. Out of the nine compounds selected for biological evaluation, three compounds - CD07230, HTS08529 and KM08871 - were found to exhibit anti-mycobacterial activity."

Journal • Infectious Disease • Respiratory Diseases • Tuberculosis

Phase II study of the anti-ganglioside GD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma (ASCO 2012) - Presentation time: Sun, Jun 3; 8:00 AM - 12:00 PM; To date, Cohort 1 (5 mg/m2 KW2871) and Cohort 2 (10 mg/m2 KW2871) have been completed safely... Cohort 3 (20 mg/m2 KW2871) has enrolled of 18 of 27 planned patients...Will be presented at study completion.

Anticipated P2 data presentation • Melanoma • Oncology